Want to see MHUAF full AI Analyst Report?
MHUAF Stock Chart & Stats
$8.77
$0.00(0.00%)
At close: 4:00 PM EDT
$8.77
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.05 - $50.09
Previous CloseN/A
Volume200.00
Average Volume (3M)258.45K
Market Cap
$5.83M
Enterprise Value-$373.79K
Total Cash (Recent Filing)$15.15M
Total Debt (Recent Filing)$8.99M
Price to Earnings (P/E)0.5
Beta0.78
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)15.09
Shares Outstanding857,914
10 Day Avg. Volume415,554
30 Day Avg. Volume258,455
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.01
P/FCF Ratio1.39
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda-0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMeihua’s low leverage and steadily growing equity and assets create durable financial flexibility. A conservatively financed balance sheet supports investment in new initiatives, cushions earnings volatility, and reduces refinancing risk over the next several quarters as the company executes strategic changes.
Sustained Positive ProfitabilityDespite recent revenue weakness, the company has maintained positive EBIT/EBITDA and net income, providing operating resilience. Continued profitability enables internal funding of operations and strategic projects, helping sustain the business through a multi-quarter transition or investment cycle.
Strategic Pivot To SaaSManagement’s formal shift toward subscription SaaS and related services is a structural change to diversify revenue and increase customer lock-in. A CEO-led task force and planned EGM signal commitment; recurring revenue could stabilize top-line and margins over several quarters once scaled.
Bears Say
Sharp Revenue DeclineA steep revenue drop materially weakens growth trajectory and reduces operating leverage. Persistently lower sales can erode pricing power, limit R&D or go-to-market investment capacity, and make it harder to restore prior profitability levels within a few quarters without new revenue streams.
Volatile Cash GenerationHighly inconsistent historical cash conversion and the recent collapse in operating/FCF substantially weaken the company’s ability to self-fund growth or absorb shocks. This volatility increases the risk that the firm will need external financing for SaaS build-out or working capital within the medium term.
Margin Compression And Falling ROEDeclining gross margins and a material drop in ROE point to deteriorating operating efficiency and lower returns on invested capital. Sustained margin pressure undermines earnings resilience and limits ability to reinvest profitably, constraining long-term value creation unless structural issues are resolved.
MHUAF FAQ
What was Meihua International Medical Technologies Co Ltd’s price range in the past 12 months?
Meihua International Medical Technologies Co Ltd lowest stock price was $2.05 and its highest was $50.09 in the past 12 months.
What is Meihua International Medical Technologies Co Ltd’s market cap?
Meihua International Medical Technologies Co Ltd’s market cap is $5.83M.
When is Meihua International Medical Technologies Co Ltd’s upcoming earnings report date?
Meihua International Medical Technologies Co Ltd’s upcoming earnings report date is Nov 16, 2026 which is in 104 days.
How were Meihua International Medical Technologies Co Ltd’s earnings last quarter?
Meihua International Medical Technologies Co Ltd released its earnings results on Apr 23, 2026. The company reported $5.228 earnings per share for the quarter, beating the consensus estimate of N/A by $5.228.
Is Meihua International Medical Technologies Co Ltd overvalued?
According to Wall Street analysts Meihua International Medical Technologies Co Ltd’s price is currently Overvalued.
Does Meihua International Medical Technologies Co Ltd pay dividends?
Meihua International Medical Technologies Co Ltd does not currently pay dividends.
What is Meihua International Medical Technologies Co Ltd’s EPS estimate?
Meihua International Medical Technologies Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Meihua International Medical Technologies Co Ltd have?
Meihua International Medical Technologies Co Ltd has 857,914 shares outstanding.
What happened to Meihua International Medical Technologies Co Ltd’s price movement after its last earnings report?
Meihua International Medical Technologies Co Ltd reported an EPS of $5.228 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.832%.
Which hedge fund is a major shareholder of Meihua International Medical Technologies Co Ltd?
Currently, no hedge funds are holding shares in MHUAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Meihua International Medical Technologies Co Ltd
Meihua International Medical Technologies Co., Ltd. is a Chinese company dedicated to the innovation, production, and distribution of a wide array of medical devices. Operating primarily within the People's Republic of China, its comprehensive product portfolio spans various regulatory classifications. The company offers numerous Class I disposable medical supplies, such as medical X-ray and dry films, dry laser imagers, gauze bandages, and examination gloves. It also provides pharmaceutical packaging, including low-density polyethylene eye drop bottles and high-density polyethylene tablet bottles. Its Class II inventory comprises critical disposable instruments and kits for medical procedures, including complete anesthesia kits, specialized medical brushes, various examination and urethral catheterization sets, endotracheal intubation devices, medical masks, anal bags, and suction connecting tubes. For Class III disposable medical devices, Meihua manufactures advanced solutions like single-use infusion pumps, sophisticated anesthesia puncture kits, and electronic pump systems. Beyond these, the company also produces disposable plastic baby bottles and components like NB/PSN rubber covers and 8.2mL folded spoons for tools and containers. It specializes in Class II 6866 medical polymer materials and products, such as transfusion equipment, pipelines, and endotracheal intubation for respiratory care, alongside traditional medical X-ray films and multi-functional self-extracting X-ray film machines. Meihua caters to a broad customer base, including hospitals, pharmacies, medical institutions, and medical equipment companies. Its products are distributed globally, reaching markets throughout Europe, North America, South America, Asia, Africa, and Oceania. Founded in 1991, the company is headquartered in Yangzhou, People's Republic of China.
Meihua International Medical Technologies Co Ltd (MHUAF) Earnings & Revenues
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors





